Peter D Koch - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Peter D Koch

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal for Immunotherapy of Cancer|December 25, 2024

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.

Msystems|March 23, 2022

High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune ResponseTai L Ng, Erika J Olson, Tae Yeon Yoo, et al.

Cell|July 8, 2022

Dissecting the treatment-naive ecosystem of human melanoma brain metastasisJana Biermann, Johannes C Melms, Amit Dipak Amin, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal for Immunotherapy of Cancer|December 25, 2024

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.

Msystems|March 23, 2022

High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune ResponseTai L Ng, Erika J Olson, Tae Yeon Yoo, et al.

Cell|July 8, 2022

Dissecting the treatment-naive ecosystem of human melanoma brain metastasisJana Biermann, Johannes C Melms, Amit Dipak Amin, et al.

Pageof 2